Radiation combined with antiangiogenic and antivascular agents

被引:55
|
作者
O'Reilly, MS
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.semradonc.2005.08.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is critical for a number of physiologic and pathophysiologic processes, and angiogenesis inhibitors are now being used in the treatment of cancer. Although antiangiogenic agents offer great therapeutic potential, preclinical and clinical trial results suggest that these agents will have a delayed onset of activity and may only induce disease stabilization for patients with advanced malignancy. The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents. Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity. The goal of this review is to provide an overview and discussion of the combination of angiogenesis inhibitors with radiation therapy. © 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [41] Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
    A Bozec
    S Lassalle
    J Gugenheim
    J-L Fischel
    P Formento
    P Hofman
    G Milano
    British Journal of Cancer, 2006, 95 : 722 - 728
  • [42] THE CLINICAL-EXPERIENCE WITH ANTIANGIOGENIC AGENTS
    MARSHALL, JL
    HAWKINS, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 1995, 36 (02) : 253 - 261
  • [43] Novel antiangiogenic agents for use in contraception
    Sharkey, AM
    Catalano, R
    Evans, A
    Charnock-Jones, DS
    Smith, SK
    CONTRACEPTION, 2005, 71 (04) : 263 - 271
  • [44] The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer
    Cumpanas, Alin Adrian
    Cimpean, Anca Maria
    Ferician, Ovidiu
    Ceausu, Raluca Amalia
    Sarb, Simona
    Barbos, Vlad
    Dema, Alice
    Raica, Marius
    ANTICANCER RESEARCH, 2016, 36 (05) : 2291 - 2295
  • [45] Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
    Bozec, A.
    Lassalle, S.
    Gugenheim, J.
    Fischel, J-L
    Formento, P.
    Hofman, P.
    Milano, G.
    BRITISH JOURNAL OF CANCER, 2006, 95 (06) : 722 - 728
  • [46] Cutaneous side effects of antiangiogenic agents
    Robert, Caroline
    BULLETIN DU CANCER, 2007, 94 : S260 - S264
  • [47] Current antiangiogenic agents in oncology and ophthalmology
    Cernak, M.
    Nogova, L.
    NEOPLASMA, 2016, 63 (01) : 10 - 17
  • [48] Gold nanoparticles as antiangiogenic and antimetastatic agents
    Zamborlin, Agata
    Voliani, Valerio
    DRUG DISCOVERY TODAY, 2023, 28 (02)
  • [49] Cutaneous genital complications of antiangiogenic agents
    Mateus, C.
    Massard, C.
    Tomasic, G.
    Wechsler, J.
    Boige, V.
    Le Cesne, A.
    Soria, J. C.
    Escudier, B.
    Robert, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
    Pozzi, Ambra
    Capdevila, Jorge H.
    PPAR RESEARCH, 2008, 2008